全球腦膜炎雙球菌疫苗市場規模（依疫苗類型、最終用戶、區域覆蓋範圍和預測）：

腦膜炎雙球菌疫苗市場規模及預測

2024 年腦膜炎雙球菌疫苗市場規模價值 48.7 億美元，預計 2032 年將達到 72 億美元，2026 年至 2032 年的複合年成長率為 5.54%。

• 腦膜炎雙球菌疫苗旨在預防腦膜炎雙球菌感染疾病，腦膜炎雙球菌感染可導致腦膜炎和敗血症等嚴重。
• 腦膜炎雙球菌疫苗預防疾病的有效率至少為 85% 至 100%，有效期至少為 2 年。
• 腦膜炎雙球菌疫苗 (MenACWY) 通常為 11-12 歲的青少年接種，16-23 歲的青少年則需要根據個人風險進行加強接種。
• 腦膜炎雙球菌疫苗一般被認為可安全用於各種人群，包括孕婦，並持續監測其副作用。

腦膜炎雙球菌疫苗的全球市場動態

影響腦膜炎雙球菌疫苗市場的關鍵市場動態是：

關鍵市場促進因素

• 腦膜炎球菌疾病發生率上升：全球腦膜炎球菌疾病報告病例數的不斷增加是疫苗市場的主要驅動力。例如，2019年，全球約有251萬例腦膜炎病例，其中128萬例為五歲以下兒童。這一令人擔憂的疫情凸顯了有效疫苗接種的迫切需求，以預防疫情爆發並保護弱勢群體。
• 政府疫苗接種計畫：例如，在美國，入學時必須接種疫苗，這導致疫苗接種率很高，尤其是在高風險青少年。
• 公共衛生計劃：世界衛生組織 (WHO) 和疫苗聯盟 (Gavi) 等全球衛生組織正在支持低收入國家的疫苗宣傳活動，並資助疫苗分發。例如，奈及利亞最近在 Gavi 的資助下推出了新型五價腦膜炎雙球菌疫苗 (Men5CV)，以應對日益成長的病菌感染發病率。
• 提高意識和教育宣傳活動：提高衛生工作者和公眾對腦膜炎球菌病菌感染嚴重性的認知將推動強調青少年和年輕人接種疫苗重要性的宣傳活動需求，這將有助於提高疫苗接種覆蓋率。

主要市場挑戰：

• 疫苗高成本：腦膜炎雙球菌疫苗的成本是疫苗接種的主要障礙，尤其是在中低收入國家。在新興市場，B群腦膜炎雙球菌疫苗等疫苗每劑售價高達150-250美元，遠高於每劑通常不到50美元的傳統兒科疫苗。如此高昂的價格使得許多人難以獲得疫苗，尤其是在醫療預算有限的地區。
• 供應和生產能力有限：腦膜炎雙球菌疫苗市場的特點是製造商數量有限，導致供應受限。根據世界衛生組織的數據，全球腦膜炎雙球菌疫苗需求量預計約為1.7億劑，而2019年的供應量估計約為2億劑。這種差異為滿足不同地區，尤其是高發地區的需求帶來了挑戰。
• 疫苗猶豫和錯誤訊息：關於疫苗安全性和有效性的錯誤訊息加劇了這個問題。在識字率低、醫療基礎設施匱乏的地區，這種猶豫是疫苗接種的主要障礙。
• 疫苗分發的物流挑戰：在偏遠和服務不足的地區分發疫苗面臨物流挑戰，阻礙了疫苗接種。在許多新興國家，醫療基礎設施不足使需要低溫運輸管理的疫苗儲存和分發變得複雜，導致疫苗接種率低。

主要市場趨勢：

• 腦膜炎球菌疾病發生率不斷上升：根據美國疾病管制與預防中心 (CDC) 預測，全球每年約有 120 萬例細菌性腦膜炎病例。發病率的上升凸顯了有效疫苗接種策略的迫切需求。
• 世界各國政府正在擴大疫苗接種計劃，將腦膜炎雙球菌疫苗納入國家疫苗接種計劃。這一趨勢針對的是不同人群，包括嬰兒、青少年、大學生以及前往流行地區的旅客。例如，隨著腦膜炎病例的增加，愛爾蘭等國家最近核准了針對青少年的MenACWY疫苗。
• 公眾意識提升：醫療保健專業人員和一般大眾對腦膜炎球菌病菌感染嚴重性的認知日益加深。教育宣傳活動有助於推廣疫苗接種，從而增加了疫苗需求。研究表明，隨著家長對腦膜炎球菌病菌感染潛在死亡率的認知不斷提高，疫苗接種率可能會上升。
• 疫苗研發技術進步：疫苗技術的創新正在推動市場發展。開發能夠預防多種血清群（例如MenABCWY）的多效價疫苗有望提高疫苗接種覆蓋率並簡化疫苗接種程序，使醫護人員和患者都能更輕鬆地接種疫苗。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 腦膜炎雙球菌疫苗市場（依疫苗類型）

• 四價疫苗
• 二價疫苗
• A血清群疫苗

5. 腦膜炎雙球菌疫苗市場（依年齡層）

• 新生兒和兒科
• 青少年期和成年早期
• 成人
• 老年人

6. 腦膜炎雙球菌疫苗市場（按通路）

• 醫院和診所
• 零售藥局
• 網路藥局

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• GlaxoSmithKline plc（UK）
• Pfizer Inc.（US）
• Sanofi SA（France）
• Baxter International Inc.（US）
• Serum Institute of India Pvt. Ltd.（India）
• Walvax Biotechnology Co., Ltd.（China）

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Meningococcal Vaccines Market Size And Forecast

Meningococcal Vaccines Market size was valued at USD 4.87 Billion in 2024 and is projected to reach USD 7.2 Billion by 2032, growing at a CAGR of 5.54% from 2026 to 2032.

• Meningococcal vaccines are designed to protect against infections caused by the bacteria Neisseria meningitidis, which can lead to serious conditions such as meningitis and sepsis.
• Meningococcal vaccines are between 85% and 100% effective in preventing disease for at least two years.
• The MenACWY vaccine is generally given to adolescents at ages 11-12, with a booster at age The MenB vaccine can be given to those aged 16-23 based on individual risk.
• Meningococcal vaccines are generally considered safe for use in various populations, including pregnant individuals, with ongoing monitoring for any adverse effects.

Global Meningococcal Vaccines Market Dynamics

The key market dynamics that are shaping the meningococcal vaccines market include:

Key Market Drivers:

• Increasing Incidence of Meningococcal Disease: The rising number of reported meningococcal disease cases globally is a significant driver for the vaccine market. For instance, in 2019, there were approximately 2.51 million cases of meningitis worldwide, with 1.28 million cases in children under five years old. This alarming prevalence highlights the critical need for effective vaccination to prevent outbreaks and protect vulnerable populations.
• Government Immunization Programs: Many governments have integrated meningococcal vaccines into their national immunization schedules, significantly boosting vaccine In the United States, for example, mandatory vaccination requirements for school and college entry ensure high coverage rates among adolescents, who are particularly at risk.
• Public Health Initiatives: Global health organizations like the World Health Organization (WHO) and Gavi, the Vaccine Alliance, support vaccination campaigns and provide funding for vaccine distribution in low-income countries. For example, Nigeria recently introduced a new 5-in-1 meningococcal vaccine (Men5CV) to combat rising cases, supported by Gavi's financial assistance.
• Awareness and Education Campaigns: Increased awareness among healthcare professionals and the general public about the severity of meningococcal disease drives demand for Campaigns emphasizing the importance of vaccination for adolescents and young adults contributing to higher immunization rates.

Key Market Challenges:

• High Cost of Vaccines: The cost of meningococcal vaccines is a significant barrier to access, particularly in low- and middle-income countries. Prices for vaccines, such as serogroup B meningococcal vaccines, can range from $150 to $250 per dose in developed markets, which is substantially higher than traditional childhood vaccines that typically cost under $50 per dose. This pricing makes it difficult for many populations to afford vaccination, especially where healthcare budgets are limited.
• Limited Supply and Manufacturing Capacity: The meningococcal vaccine market is characterized by a limited number of manufacturers, leading to supply constraints. According to WHO data, the global demand for meningococcal vaccines is projected at around 170 million doses, while the estimated supply was about 200 million doses in 2019. This disparity creates challenges in meeting the needs of various regions, particularly those with high disease prevalence.
• Vaccine Hesitancy and Misinformation: Vaccine hesitancy remains a critical challenge, exacerbated by misinformation regarding vaccine safety and effectiveness. In regions with lower literacy rates and poor healthcare infrastructure, this hesitancy can significantly impede vaccination Public reluctance to vaccinate can lead to lower coverage rates and increased vulnerability to outbreaks.
• Logistical Challenges in Vaccine Distribution: Delivering vaccines to remote or underserved areas poses logistical challenges that can hinder vaccination efforts. In many developing countries, inadequate health infrastructure complicates the storage and distribution of vaccines that require cold chain management, resulting in lower vaccination coverage.

Key Market Trends:

• Growing Incidence of Meningococcal Disease: The increasing prevalence of meningococcal disease is a significant driver of the vaccine According to the CDC, approximately 1.2 million cases of bacterial meningitis are projected to occur globally each year. This rising incidence underscores the urgent need for effective vaccination strategies.
• Expansion of Vaccination Programs: Governments worldwide are expanding their vaccination programs to include meningococcal vaccines in national immunization schedules. This trend targets various demographics, including infants, adolescents, college students, and travelers to endemic For instance, countries like Ireland have recently approved the MenACWY vaccine for teenagers due to rising meningitis cases.
• Increased Public Awareness: There is a growing awareness among healthcare professionals and the general public regarding the seriousness of meningococcal disease. Educational campaigns have been instrumental in promoting vaccination, leading to higher demand for vaccines. Research indicates that as parents become more aware of the potential fatality associated with meningococcal disease, vaccine uptake is likely to increase.
• Technological Advancements in Vaccine Development: Innovations in vaccine technology are driving the market forward. The development of multivalent vaccines that protect against multiple serogroups (e.g., MenABCWY) is expected to enhance coverage and simplify vaccination schedules, making it easier for healthcare providers and patients alike.

Global Meningococcal Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the meningococcal vaccine market:

North America:

• North America is expected to hold an estimated market share of 40.2% in 2024 and has been a leading region with revenues around USD 2.88 Billion in This dominance is attributed to high awareness levels regarding meningococcal diseases and effective vaccination strategies.
• The region benefits from a well-established healthcare system that supports widespread vaccination Strong healthcare infrastructure facilitates easy access to vaccines and ensures efficient distribution, contributing to higher immunization rates.
• Strong government initiatives, such as those from the Centers for Disease Control and Prevention (CDC), promote routine immunization against meningococcal The CDC recommends meningococcal vaccination for adolescents, which significantly boosts vaccine uptake.
• Major pharmaceutical companies in North America, such as GlaxoSmithKline (GSK) and Pfizer, invest heavily in R&D to develop new vaccines and improve existing formulations. This focus on innovation ensures a steady supply of effective vaccines that address emerging strains of Neisseria meningitidis.

Asia Pacific:

• The Asia Pacific region is projected to exhibit the highest compound annual growth rate (CAGR) of 14.7% from 2019 to 2026 in the meningococcal vaccines market, driven by increasing healthcare investments and growing awareness about meningococcal diseases.
• Many governments in the region are expanding their immunization programs to include meningococcal vaccines. For instance, the Indian government has initiated campaigns to vaccinate children against meningitis, recognizing the need to combat rising disease prevalence.
• Rising healthcare spending in developing countries enhances access to vaccines. According to various reports, countries in Asia Pacific are investing more in healthcare infrastructure and vaccine distribution, facilitating broader access to life-saving vaccinations.
• The presence of both domestic and international pharmaceutical companies focusing on vaccine development is increasing competition and innovation in the market. This includes partnerships aimed at improving production and distribution networks within Asia Pacific.

Global Meningococcal Vaccines Market: Segmentation Analysis

The Global Meningococcal Vaccines Market is Segmented on the basis of Product Type, End-User, And Geography.

Meningococcal Vaccines Market, By Product Type

• Quadrivalent Vaccines
• Bivalent Vaccines
• Serogroup A
• Serogroup B
• Serogroup X

Based on Product Type, The market is classified into Quadrivalent Vaccines, Bivalent Vaccines, Serogroup A, Serogroup B, and Serogroup X. Quadrivalent vaccines, which protect against four serogroups of Neisseria meningitidis (A, C, W, and Y), dominate the meningococcal vaccines market with an estimated share of approximately 60% in 2023. This high market share is attributed to their broad coverage and effectiveness in preventing meningococcal disease.

Meningococcal Vaccines Market, By End-User

• Children
• Pre-teens or Teens
• Adults

Based on End-User, the market is classified into Children, Pre-teens or Teens, and Adults. The pre-teens and teens segment accounted for approximately 57.9% of the market share in 2022. This high percentage reflects the increased susceptibility of this age group to meningococcal disease due to their developing immune systems and social interactions.

Meningococcal Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, The Global Meningococcal Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to hold an estimated market share of 40.2% in 2024 and has been a leading region with revenues of around USD 2.88 Billion in 2021. This dominance is attributed to high awareness levels regarding meningococcal diseases and effective vaccination strategies.

Key Players

The "Global Meningococcal Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as GlaxoSmithKline plc., Pfizer, Merck & Co., Serum Institute of India, Sanofi, Johnson & Johnson, AstraZeneca, Bavarian Nordic, BIO MED Private Limited, Chongqing Zhifei Biological Products Co., Bio-Manguinhos.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above- mentioned players globally.

• Meningococcal Vaccine Market Recent Developments
• In April 2024, GlaxoSmithKline plc announced the acceptance of their 5-in-1 meningococcal ABCWY vaccine (MenABCWY) for regulatory review by the U.S. FDA, which combines the protective elements of their existing vaccines to target five primary serogroups of Neisseria meningitidis (A, B, C, W, and Y).
• In July 2023, the Serum Institute of India launched MenFive(R), the first conjugate vaccine designed to protect against five predominant causes of meningococcal meningitis, specifically targeting serogroups A, C, W, Y, and X, and aimed at preventing outbreaks in the African meningitis belt.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Meningococcal Vaccine Market, By Type of Vaccine

• Vaccines classified as quadrivalents
• Vaccines classified as bivalents
• Vaccines against Serogroup A

5. Meningococcal Vaccine Market, By Age Range

• Newborns and Children
• Adolescents and Young Adults
• Adults
• Elderly

6. Meningococcal Vaccine Market, By Channel of Distribution

• Hospitals and clinics
• Retail Pharmacies
• Online pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GlaxoSmithKline plc (U.K.)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• Baxter International Inc. (U.S.)
• Serum Institute of India Pvt. Ltd. (India)
• Walvax Biotechnology Co., Ltd. (China)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References